Chembio Diagnostics, Inc. (CEMI)

1 member of Congress has disclosed 4 trades in Chembio Diagnostics, Inc. (CEMI) via STOCK Act filings. The most recent disclosure was a sale by Tom Malinowski on 24 March 2020. Aggregate disclosed activity totals roughly $32K in sales (midpoint estimates from bracketed disclosure amounts).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Price data is not available for CEMI
This ticker may have been delisted, renamed, or is not publicly quoted, so no live price, statistics or chart can be shown. The congressional trades disclosed for it are listed below.

Congressional Trading Activity for CEMI

4 transactions
Compliance: 50%
Tom Malinowski24 Mar 202026 Aug 2021SaleStock$1,001 - $15,000N/A
Tom Malinowski24 Mar 202026 Aug 2021SaleStock$1,001 - $15,000N/A
Tom Malinowski19 Mar 20205 Mar 2021SaleStock$1,001 - $15,000N/A
Tom Malinowski19 Mar 202030 Jul 2021SaleStock$1,001 - $15,000N/A

Stock Overview

Market Data

Market Cap

$16.71M

Volume

351.64K

Beta

1.86

P/E Ratio

-0.63

Fundamentals

EPS

$-0.72

Div. Yield

-

Open

$0.45

Day Range

$0.46 – $0.46

Company Information

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Exchange
NASDAQ · USD
Country
US
CEO
Richard L. Eberly
IPO Date
2000-10-18
Website
chembio.com

Chembio Diagnostics, Inc., along with its subsidiaries, specializes in creating, producing, and bringing to market point-of-care (POC) diagnostic tests used for identifying and diagnosing various diseases. Their current product offerings include test...

Earnings

Recent Quarters

Q4 202229 Mar
EPS$-0.02
Q3 20223 Nov
EPS$-0.21
Q2 20224 Aug
EPS$-0.23
Q1 20225 May
EPS$-0.29
Miss 38.1%
Q4 20213 Mar
EPS$-0.32
Miss 39.1%
Q3 20214 Nov
EPS$-0.23
Miss 9.5%
Q2 20215 Aug
EPS$-0.35
Beat 7.9%
Q1 20216 May
EPS$-0.22
Beat 26.7%
Q4 202011 Mar
EPS$-0.35
Miss 25.0%
Q3 20205 Nov
EPS$-0.28
Miss 16.7%
Q2 20206 Aug
EPS$-0.40
Beat 2.4%
Q1 20204 May
EPS$-0.25
Miss 13.6%
Q4 201912 Mar
EPS$-0.23
Beat 8.0%
Q3 20197 Nov
EPS$-0.22
Miss 15.8%
Q2 20196 Aug
EPS$-0.19
Miss 18.8%
Q1 20191 May
EPS$-0.14
Beat 0.0%
Q4 20187 Mar
EPS$-0.21
Miss 23.5%
Q3 20188 Nov
EPS$-0.16
Miss 6.7%
Q2 20188 Aug
EPS$-0.12
Miss 71.4%
Q1 20189 May
EPS$-0.05
Beat 50.0%
Q4 20178 Mar
EPS$-0.16
Miss 33.3%
Q3 20178 Nov
EPS$-0.05
Beat 54.5%
Q2 20179 Aug
EPS$-0.18
Miss 12.5%
Q1 20179 May
EPS$-0.13
Beat 38.1%
Q4 20167 Mar
EPS$-0.21
Miss 23.5%
Q3 201610 Nov
EPS$-0.19
Miss 11.8%
Q2 201611 Aug
EPS$-0.24
Miss 200.0%
Q1 201612 May
EPS$-0.03
Beat 62.5%
Q4 20158 Mar
EPS$-0.07
Beat 0.0%
Q3 201512 Nov
EPS$-0.05
Beat 44.4%
Q2 20156 Aug
EPS$-0.07
Miss 133.3%
Q1 20157 May
EPS$-0.07
Beat 12.5%
Q4 20145 Mar
EPS$-0.05
Miss 66.7%
Q3 20146 Nov
EPS$-0.03
Miss 50.0%
Q2 20147 Aug
EPS$-0.02
Miss 14.3%
Q1 20148 May
EPS$-0.02
Miss 100.0%
Q4 20136 Mar
EPS$-0.03
Miss 169.3%
Q3 20137 Nov
EPS$0.07
Miss 12.5%
Q2 20138 Aug
EPS$-0.03
Miss 18.2%
Q1 20139 May
EPS$0.04
Beat 71.5%
Q4 20127 Mar
EPS$0.06
Beat 20.0%
Q3 201213 Nov
EPS$-0.06
Miss 200.0%
Q2 20129 Aug
EPS$0.04
Beat 33.3%
Q1 20128 May
EPS$0.08
Q4 20118 Mar
EPS$0.72
Q3 20113 Nov
EPS$0.06
Q2 20114 Aug
EPS$0.02
Q1 20115 May
EPS$-0.02
Q4 20103 Mar
EPS$0.24
Q3 20104 Nov
EPS$0.02
Q2 201029 Jul
EPS$0.08
Beat 200.0%
Q2 201028 Jul
EPS$0.07
Q4 20095 Mar
EPS$0.01
Q3 20094 Nov
EPS$0.03
Q2 20096 Aug
EPS$0.01
Q1 20097 May
EPS$-0.04
Q4 200818 Mar
EPS$-0.06
Q3 200812 Nov
EPS$-0.03
Beat 61.7%
Q2 20084 Aug
EPS$-0.08
Beat 0.0%
Q1 200812 May
EPS$-0.08
Beat 50.0%
Q4 200712 Mar
EPS$-2.56
Miss 220.0%
Q3 20071 Nov
EPS$-0.37
Q2 20079 Aug
EPS$-0.64
Q1 200711 May
EPS$-0.72
Beat 30.8%
Q4 200629 Mar
EPS$-1.84
Miss 91.7%
Q4 200628 Mar
EPS$-0.97
Q2 200611 Aug
EPS$-0.90
Q1 200612 May
EPS$-1.12
Q4 200530 Mar
EPS$-0.84
Q3 200514 Nov
EPS$-0.82
Q2 200512 Aug
EPS$-0.94
Q1 200513 May
EPS$-0.71
Q4 200431 Mar
EPS$-1.04
Q3 200415 Nov
EPS$-1.32
Q2 200417 Aug
EPS$-0.95
Q1 200414 May
EPS$-0.15
Q4 200314 Jan
EPS$0.00
Q2 200313 Aug
EPS$-0.01
Q1 20033 Jun
EPS$0.05
Q4 200219 Feb
EPS$-0.04
Q3 200227 Dec
EPS$-0.09
Q2 200213 Aug
EPS$-2.29
Q1 200213 May
EPS$-0.20
Q4 200119 Feb
EPS$-0.04
Q3 200128 Dec
EPS$-0.52
Q2 200113 Aug
EPS$0.12
Q4 200013 Feb
EPS$-1.70
Q3 200014 Nov
EPS$-1.43
Q2 200018 Aug
EPS$-0.81

No dividend data available for this stock.

Stock Splits

Split History

30 May 2012Reverse Split
Ratio1:8
12 Mar 2004Reverse Split
Ratio1:17

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about CEMI

Which members of Congress have traded CEMI?
1 member of Congress has disclosed 4 trade in Chembio Diagnostics, Inc. (CEMI) under the STOCK Act: Tom Malinowski.
When was CEMI most recently disclosed by Congress?
The most recent CEMI disclosure was a sale by Tom Malinowski on 24 March 2020.
What is the total disclosed congressional trading volume for CEMI?
Members of Congress have disclosed approximately $32K in CEMI sales (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in CEMI?
This CEMI page updates as soon as new STOCK Act disclosures are filed for Chembio Diagnostics, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.